Sebi will act against pharma cos in case of non-disclosure of material information, says Tyagi

Mumbai: Markets regulator Sebi on Thursday said it would take action against pharma companies if they are found not sharing information on material events like inspections and reports by the US FDA.

“It is necessary to share material information even now. If the US FDA (Food and Drug Administration) has taken any action against them (pharmaceutical companies) and they are not disclosing it, if that comes before us, we will take action,” Sebi chairman Ajay Tyagi told reporters here.

He was replying to a specific question pertaining to pharma companies not disclosing actions by drug regulators in foreign markets like the US FDA undertaking inspections of their facilities and passing orders.

There have allegedly been instances of such happenings not being properly disclosed to the investors.

Tyagi said such information that constitutes to be “material information” should be shared with the stock exchanges immediately by the respective companies.

India is one of the world’s biggest pharma exporters and many of the domestic players in the sector are listed on the exchanges.

  • Related Posts

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    New Delhi: The Parliamentary Panel on Health and Family Welfare has recommended various significant regulatory changes in the regulation of medical devices, including decentralisation of approval for all medical devices…

    Diabetic drug metformin found to act on brain

    NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory